4D Molecular Therapeutics Posts $0.43 EPS, $85M Q4 Revenue Beat Expectations
4D Molecular Therapeutics posted Q4 2025 EPS of $0.43, reversing an expected $0.53 loss and delivering a 180.75% earnings surprise. Revenue reached $85.09 million, a 147.86% beat driven by an $85 million upfront collaboration payment from Otsuka Pharmaceutical for its 4D-150 program.
1. Q4 Earnings Outperform Expectations
4D Molecular delivered Q4 2025 EPS of $0.43 per share, reversing the expected $0.53 loss and representing a 180.75% earnings surprise compared to analyst estimates.
2. Collaboration Payment Drives Revenue
Revenue for the quarter reached $85.09 million, surpassing estimates by 147.86%, primarily due to an $85 million upfront payment from Otsuka Pharmaceutical under the 4D-150 Asia-Pacific collaboration agreement.
3. Full-Year Financial Improvement
For full-year 2025, net loss narrowed to $140 million (-$2.42 per share) from $161 million (-$2.98), with revenue concentrated in Q4 collaboration income and signaling tighter cost management.
4. Strong Balance Sheet Provides Runway
As of December 31, 2025, the company held $514 million in cash and equivalents, maintained a debt-to-equity ratio of 0.042 and a current ratio of 9.39, supporting operations into the second half of 2028.